Genmab A/S (Nasdaq: GMAB) today announced updated follow-up analyses from a Phase 2 trial evaluating petosemtamab, an ...

Amgen (NASDAQ:AMGN) today announced landmark interim Phase 3 results showing that IMDELLTRA® (tarlatamab-dlle) in combination with AstraZeneca's IMFINZI® (durvalumab) reduced the risk of death by 58% ...

Howard Smith’s urologist told him his prostate cancer was not the kind you die with: “It’s the one that’s going to kill you.” ...

Legal and election experts said the latest move from the Justice Department to block certification in Alaska’s Senate race ...

Longtime Fred Hutch epidemiologist Dr. Christopher Li, who joined the center in 2002, has been promoted to senior vice ...

Attorney General Keith Ellison claims that the iconic French beauty brand knowingly marketed chemical hair relaxer products ...

Natural killer cells reprogrammed inside mice eliminated lymphoma tumors and helped damaged livers heal, though whether this ...

The test offers the chance to choose embryos without BRCA mutations. But the process can be expensive and time-consuming, and ...

A first-in-human clinical trial co-led by researchers at University Health Network's Princess Margaret Cancer Centre has found early signs that a novel immunotherapy may help some patients with ...

A new preclinical study suggests that attacking triple-negative breast cancer (TNBC) in two ways at once can kill cancer ...

Learn how researchers at St. Jude, led by Hai Dao, PhD, discovered the mechanisms behind PARP1-mediated DNA repair.

The world’s first major trial of a personalised therapeutic cancer vaccine has been hailed a ‘foundational shift’ in how we ...